Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2018 Sep 4;12(9):e0006706.
doi: 10.1371/journal.pntd.0006706. eCollection 2018 Sep.

Evaluation of Auramine O staining and conventional PCR for leprosy diagnosis: A comparative cross-sectional study from Ethiopia

Affiliations
Comparative Study

Evaluation of Auramine O staining and conventional PCR for leprosy diagnosis: A comparative cross-sectional study from Ethiopia

Selfu Girma et al. PLoS Negl Trop Dis. .

Abstract

Background: Diagnosis of leprosy mainly relies on clinical examination due to the inconsistent sensitivity and poor reproducibility of the current laboratory tests. Utilisation of alternative methods to the standard Ziehl Neelsen (ZN), Fite-Faraco (FF) and Haematoxylin and Eosin (H&E) staining procedures may eventually improve leprosy diagnosis.

Methodology/principal findings: In this comparative study, the performance of the fluorescent Auramine O (AO) staining and polymerase chain reaction (PCR) was assessed with different skin samples using a combination of ZN, FF and H&E staining as the gold standard. AO, ZN, FF, H&E and PCR tests were performed on slit skin smears (SSS) and/or punch biopsies collected from 141 clinically confirmed leprosy cases and 28 non-leprosy skin samples. DNA was extracted from punch biopsies using two different methods with or without mechanical lysis. Sensitivities were 87.6%, 59.3% and 77% for H&E, ZN and FF, respectively, whereas it reached 65.5% and 77.9% for AO in SSS and tissue sections and 91.1% for PCR in tissue samples. Morover, samples with low bacillary index, sensitivity of AO staining (61.8%) was similar to FF (60%, p>0.05) and lower than PCR (86.6%, p<0.05). Sensitivity of PCR also increased (96.8%, p<0.05) when mechanical lysis was used during DNA extraction compared to enzymatic treatment alone (84.6%).

Conclusions/significance: Our results showed that for diagnostic purposes, analysis of skin section is more sensitive than SSS, especially for samples with low bacillary load. AO staining on SSS and tissue sections was not significantly better than other routine diagnostic tests but considerably more user friendly. The sensitivity of PCR was higher than current standard methods and increased when combined with more efficient DNA extraction using mechanical and chemical lysis. Therefore, we recommend AO staining for the diagnosis of leprosy in lower health facilities such as health centres and district hospitals and PCR diagnosis at referral level and research centres.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interest exist.

Figures

Fig 1
Fig 1. Histopathological repartition of the gold standard positive and negative samples with the number of positive sample and positivity rate (%) for each laboratory tests–HB: High bacillary load included samples from the LL, BL and BB groups; LB: Low bacillary load included samples from the BT, TT, INT and NEG groups–The graphic show the high positivity rate for AO-tissue and PCR in all groups compared to other methods.
Fig 2
Fig 2
Auramine O stained M.leprae in FFPE tissue section under 40X objective of light-emitting diode fluorescence microscope A: Sample with high BI B. Sample with low BI.

References

    1. Britton WJ, Lockwood DN. Leprosy. Lancet (London, England). 2004; 363: 1209–19. - PubMed
    1. Ridley DS, Jopling WH. A classification of leprosy for research purposes. Leprosy review. 1962; 33: 119–28. - PubMed
    1. FMoH. Tuberculosis, Leprosy andTB/HIV Prevention and Control Programme Addis Ababa: Federal Ministry of Health Ethiopia; 2008.
    1. WHO. WHO model prescribing information: drugs used in leprosy Geneva: World Health Organization; 1998.
    1. WHO. Global leprosy update, 2016: accelerating reduction of disease burden Geneva: World Health Organization; 2017. - PubMed

Publication types